MCID: BLD034
MIFTS: 60

Bile Duct Carcinoma

Categories: Rare diseases, Cancer diseases, Liver diseases, Gastrointestinal diseases

Aliases & Classifications for Bile Duct Carcinoma

MalaCards integrated aliases for Bile Duct Carcinoma:

Name: Bile Duct Carcinoma 12 14 69
Bile Duct Cancer 49 51 40
Bile Duct Neoplasms 41 69
Malignant Tumor of Extrahepatic Bile Duct 69
Carcinoma of Extrahepatic Bile Duct 69
Extrahepatic Bile Duct Cancer 49

Classifications:



External Ids:

Disease Ontology 12 DOID:4897
MeSH 41 D001650
NCIt 46 C27814
SNOMED-CT 64 70179006

Summaries for Bile Duct Carcinoma

NIH Rare Diseases : 49 The following summary is from Orphanet, a European reference portal for information on rare diseases and orphan drugs.Orpha Number: 70567Disease definitionCholangiocarcinoma (CCA) is a biliary tract cancer (BTC, see this term) originating in the epithelium of the biliary tree, either intra or extra hepatic.EpidemiologyThe prevalence is unknown but it accounts for approximately 3% of gastrointestinal tumors and 10-15% of all hepatobiliary malignancies.Clinical descriptionCCA can occur in the intra or extra-hepatic biliary tract. A specific type of extra-hepatic CCA known as a Klatskin tumor (see this term) occurs at the junction where the left and right hepatic bile ducts meet the common bile duct (CBD). It is slightly more prevalent in males than females (1.3:1.0) and usually presents in the fifth to seventh decade of life. Clinical manifestations are not usually noted until an advanced disease stage. Extra-hepatic CCA manifests with signs of cholestasis (jaundice, pale stools, dark urine, pruritus), malaise, weight loss and/or progressive weakness. Intra-hepatic CCA may present with an abdominal mass or with non-specific symptoms of decreased appetite, weight loss, abdominal pain and malaise.EtiologyThe etiology is unknown and most cases of CCA occur sporadically. Risk factors include primary sclerosing cholangitis (see this term), secondary sclerosing cholangitis, chronic typhoid carriage, parasitic infections (Opisthochis viverrini and Clonorchis sinensis), exposure to thorotrast (x-ray contrast medium) and choledochal cysts, all of which cause chronic biliary inflammation.Diagnostic methodsDiagnosis is suspected on clinical and laboratory findings. Serum carbohydrate antigen (CA) 19-9 is the glycoprotein tumor marker most often used in the diagnosis of CCA. It is found to be elevated in 85% of patients. Increased CEA levels are also noted. Extra-hepatic tumors cause increased levels of alkaline phosphate (ALP), conjugated bilirubin and gamma-glutamyl transpeptidase (GGT) while intra-hepatic have only slightly elevated ALP levels. Abdominal imaging, visualization of the biliary tree and biopsies of the lesion are necessary for diagnosis. Magnetic resonance cholangiopancreatography (MRCP) provides information on intrahepatic metastases, biliary anatomy and tumor extension and is used in the staging of CCA. It has been advocated to replace endoscopic retrograde cholangiopancreatography (ERCP), a more invasive method. Visualization of the biliary tree and samples through brush cytology or bile duct biopsies are obtained with ERCP. A needle biopsy is performed in those with a liver mass. Extra-hepatic CCA is further divided into anatomical subtypes according to the Bismuth classification and a disease stage is given. Ultrasound, and contrast enhanced helical computerized computed tomography (CT) can be used in visualizing the extent of disease.Differential diagnosisIntra-hepatic CCA is often mistaken for metastatic adenocarcinoma. Carcinoma of the gallbladder (see this term), benign strictures and Mirizzi syndrome should be excluded.Management and treatmentSurgical resection is the only potentially curative treatment for CCA but recurrences after surgery are frequent. Unfortunately CCA is often diagnosed as unresectable because of local extension and/or metastases. Distal CCA arising from the CBD is often treated by pancreatoduodenectomy. More proximal CCA needs hepatic resection. Palliative management involves biliary drainage by inserting metal stents in the biliary tree to release the blockage. Adjuvant chemotherapy after surgery or palliative chemotherapy for unresectable CCA is indicated. Gemcitabine combined with cisplatin therapy is the standard treatment for unresectable biliary tract cancers, including CCA.PrognosisAs proximal CCA is usually not diagnosed until a late stage of disease, prognosis is poor with 5-year survival rates of 20-50% after resection and almost 0% in unresectable tumors. Death is often due to biliary sepsis, cancer cachexia, malnutrition and liver failure.Visit the Orphanet disease page for more resources. Last updated: 9/1/2012

MalaCards based summary : Bile Duct Carcinoma, also known as bile duct cancer, is related to biliary tract neoplasm and bile duct adenocarcinoma, and has symptoms including gastrointestinal gas, nausea and vomiting and icterus. An important gene associated with Bile Duct Carcinoma is KRT7 (Keratin 7), and among its related pathways/superpathways are Cytokine Signaling in Immune system and Gastric cancer. The drugs Oxaliplatin and Pancrelipase have been mentioned in the context of this disorder. Affiliated tissues include liver, testes and lung, and related phenotypes are cellular and cardiovascular system

Disease Ontology : 12 A bile duct cancer that has material basis in abnormally proliferating cells derives from epithelial cells.

MedlinePlus : 40 Your liver makes a digestive juice called bile. Your gallbladder stores it between meals. When you eat, your gallbladder pushes the bile into tubes called bile ducts. They carry the bile to your small intestine. The bile helps break down fat. It also helps the liver get rid of toxins and wastes. Bile duct cancer is rare. It can happen in the parts of the bile ducts that are outside or inside the liver. Cancer of the bile duct outside of the liver is much more common. Risk factors include having inflammation of the bile duct, ulcerative colitis, and some liver diseases. Symptoms can include Jaundice Itchy skin Fever Abdominal pain Tests to diagnose bile duct cancer may include a physical exam, imaging tests of the liver and bile ducts, blood tests, and a biopsy. Treatments include surgery, radiation therapy, and chemotherapy. NIH: National Cancer Institute

Related Diseases for Bile Duct Carcinoma

Diseases related to Bile Duct Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 245)
# Related Disease Score Top Affiliating Genes
1 biliary tract neoplasm 32.1 CDX2 KRT7 MUC1 MUC2 MUC4 TP53
2 bile duct adenocarcinoma 31.4 CDH1 KRT19 KRT7 MUC1 MUC2 TP53
3 extrahepatic bile duct adenocarcinoma 31.4 CDH1 NCAM1
4 bile duct cystadenocarcinoma 31.0 KRT20 KRT7 MUC1 MUC2
5 intrahepatic cholangiocarcinoma 30.9 CCND1 CDH1 CDX2 KRT19 KRT20 KRT7
6 cholangiocarcinoma 30.5 CDH1 CDX2 KRT19 KRT20 KRT7 MUC1
7 adenocarcinoma 30.3 CCND1 CDH1 MUC1 MUC4 PTGS2 TP53
8 pancreatic ductal adenocarcinoma 30.2 CDH1 MUC1 MUC4 TP53
9 renal cell carcinoma, nonpapillary 29.1 CDH1 FASLG KRT19 KRT20 KRT7 MUC1
10 adenosquamous bile duct carcinoma 12.4
11 bile duct carcinoma in situ 12.2
12 common bile duct neoplasm 12.2
13 distal biliary tract carcinoma 11.5
14 klatskin's tumor 11.1
15 extrahepatic bile duct small cell adenocarcinoma 11.1
16 mucinous intrahepatic cholangiocarcinoma 10.6 CDX2 MUC2
17 cerebral convexity meningioma 10.6 CDH1 TP53
18 cystic basal cell carcinoma 10.6 KRT20 KRT7
19 pancreatic intraductal papillary-mucinous neoplasm 10.6 MUC1 MUC2
20 gallbladder signet ring cell adenocarcinoma 10.6 KRT7 MYC
21 spiradenoma 10.5 KRT7 MUC1 TP53
22 protoplasmic astrocytoma 10.5 PTGS2 TP53
23 malignant spiradenoma 10.5 KRT7 TP53
24 cap polyposis 10.5 MUC2 MUC4
25 lung acinar adenocarcinoma 10.5 KRT20 KRT7
26 tumor of exocrine pancreas 10.5 MUC1 MUC2
27 balanitis xerotica obliterans 10.5 CCND1 PTGS2 TP53
28 pre-malignant neoplasm 10.5 CCND1 CDH1 TP53
29 chronic ethmoiditis 10.5 MUC1 MUC2 MUC4
30 eccrine sweat gland neoplasm 10.5 KRT20 KRT7 TP53
31 seminal vesicle adenocarcinoma 10.5 KRT20 KRT7
32 transverse colon cancer 10.5 KRT20 KRT7
33 papillary serous adenocarcinoma 10.5 KRT20 KRT7 TP53
34 large intestine adenocarcinoma 10.5 CDH1 KRT20 KRT7
35 linitis plastica 10.5 CDH1 KRT20 KRT7
36 adenoid squamous cell carcinoma 10.5 CDH1 KRT20 KRT7
37 glycogen-rich clear cell breast carcinoma 10.5 KRT20 KRT7 TP53
38 microinvasive gastric cancer 10.5 CDH1 CDX2 MUC2
39 ethmoid sinusitis 10.5 MUC1 MUC2 MUC4
40 pharynx cancer 10.5 CCND1 CDH1 TP53
41 nasal cavity adenocarcinoma 10.5 CDX2 KRT7 TP53
42 keratocystic odontogenic tumor 10.5 CCND1 PTGS2 TP53
43 dermoid cyst 10.5 KRT20 KRT7 MUC1
44 mucinous ovarian cystadenoma 10.5 CDX2 KRT7 MUC1
45 spindle cell carcinoma 10.5 CDH1 KRT7 MUC1
46 tongue cancer 10.5 CCND1 CDH1 TP53
47 tn polyagglutination syndrome 10.5 MUC1 MUC2 MUC4
48 cerebral primitive neuroectodermal tumor 10.5 MUC1 MYC TP53
49 inverted papilloma 10.5 KRT20 KRT7 TP53
50 adenomyoma 10.5 KRT7 MUC1 MUC4

Graphical network of the top 20 diseases related to Bile Duct Carcinoma:



Diseases related to Bile Duct Carcinoma

Symptoms & Phenotypes for Bile Duct Carcinoma

UMLS symptoms related to Bile Duct Carcinoma:


gastrointestinal gas, nausea and vomiting, icterus, heartburn, dyspepsia, diarrhea, constipation, abdominal pain

MGI Mouse Phenotypes related to Bile Duct Carcinoma:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.18 NCAM1 PTGS2 TP53 MYC FASLG KRT19
2 cardiovascular system MP:0005385 10.17 PTGS2 RPSA TP53 FASLG MYC KRT19
3 digestive/alimentary MP:0005381 10.07 PTGS2 TP53 KRT19 CCND1 CDH1 MAPK8
4 endocrine/exocrine gland MP:0005379 10.06 PTGS2 RPSA TP53 MYC KRT19 CCND1
5 integument MP:0010771 9.91 PTGS2 TP53 MYC FASLG ABCC3 KRT19
6 liver/biliary system MP:0005370 9.7 MYC PTGS2 TP53 ABCC2 FASLG ABCC3
7 neoplasm MP:0002006 9.65 PTGS2 TP53 KRT19 CCND1 CDH1 MAPK8
8 reproductive system MP:0005389 9.28 PTGS2 TP53 MYC FASLG KRT19 CCND1

Drugs & Therapeutics for Bile Duct Carcinoma

Drugs for Bile Duct Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 222)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Oxaliplatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 61825-94-3 43805 6857599 5310940 9887054
2
Pancrelipase Approved, Investigational Phase 4,Phase 2,Phase 1,Early Phase 1 53608-75-6
3
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
4 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1
5 pancreatin Phase 4,Phase 2,Phase 1,Early Phase 1
6 Analgesics Phase 4,Phase 3
7 Anti-Inflammatory Agents Phase 4,Phase 3
8 Antirheumatic Agents Phase 4,Phase 1
9 Gastrointestinal Agents Phase 4,Phase 3,Phase 2
10 Peripheral Nervous System Agents Phase 4,Phase 3
11 Analgesics, Non-Narcotic Phase 4
12 Anti-Inflammatory Agents, Non-Steroidal Phase 4
13 Cyclooxygenase 2 Inhibitors Phase 4
14 Cyclooxygenase Inhibitors Phase 4
15 arginine Nutraceutical Phase 4
16 Omega 3 Fatty Acid Nutraceutical Phase 4
17 Cola Nutraceutical Phase 4,Phase 3,Phase 1,Phase 2
18
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
19
Fluorouracil Approved Phase 2, Phase 3, Phase 1 51-21-8 3385
20
Capecitabine Approved, Investigational Phase 3,Phase 2,Phase 1 154361-50-9 60953
21
Irinotecan Approved, Investigational Phase 2, Phase 3,Phase 1 97682-44-5, 100286-90-6 60838
22
Levoleucovorin Approved, Investigational Phase 2, Phase 3,Phase 1 68538-85-2
23
Trioxsalen Approved Phase 3,Phase 2 3902-71-4 5585
24
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 2767 441203 84093
25
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
26
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
27
Ondansetron Approved Phase 3 99614-02-5 4595
28
Methylphenidate Approved, Investigational Phase 3 20748-11-2, 113-45-1 4158
29
Morphine Approved, Investigational Phase 3 57-27-2 5288826
30
Melphalan Approved Phase 2, Phase 3 148-82-3 460612 4053
31
Citalopram Approved Phase 3 59729-33-8 2771
32
leucovorin Approved, Nutraceutical Phase 2, Phase 3,Phase 1 58-05-9 143 6006
33
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3,Phase 1 59-30-3 6037
34 Pancreatic Polypeptide Investigational Phase 3,Phase 2,Phase 1 59763-91-6
35 Anti-Infective Agents Phase 3,Phase 2,Phase 1
36 Antimetabolites Phase 3,Phase 2,Phase 1
37 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
38 Antiviral Agents Phase 3,Phase 2,Phase 1
39 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
40 Dermatologic Agents Phase 3,Phase 2,Phase 1
41 Photosensitizing Agents Phase 3,Phase 2,Phase 1
42 Calcium, Dietary Phase 2, Phase 3,Phase 1
43 Alkylating Agents Phase 2, Phase 3,Phase 1
44 Dihematoporphyrin Ether Phase 3,Phase 2
45 Ether Phase 3,Phase 2
46 Adjuvants, Anesthesia Phase 3
47 Analgesics, Opioid Phase 3
48 Anesthetics Phase 3
49 Anesthetics, General Phase 3
50 Anesthetics, Intravenous Phase 3

Interventional clinical trials:

(show top 50) (show all 171)

# Name Status NCT ID Phase Drugs
1 Effects of Preoperative Immunonutrition in Patients Undergoing Hepatectomy Unknown status NCT01256047 Phase 4
2 Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer Unknown status NCT00274885 Phase 4 oxaliplatin
3 Comparing Covered Self-expandable Metallic Stent (SEMS) Above/Across the Sphincter of Oddi Completed NCT01041612 Phase 4
4 Effects of Preoperative Immunonutrition in Patients Undergoing Pancreaticoduodenectomy Completed NCT01256034 Phase 4
5 Biliary Metal Stent Study: Metal Stents for Management of Distal Malignant Biliary Obstruction Completed NCT00280709 Phase 4
6 Cyclooxygenase-2 Inhibitor for Adjuvant Anticancer Effect in Patients With Biliary-pancreas Cancer Enrolling by invitation NCT01111591 Phase 4 Cox2 inhibitor (Celecoxib)
7 RFA RCT for Pancreatic or Bile Duct Cancer Unknown status NCT02166190 Phase 3
8 Early Enteral Feeding After Pylorus Preserving Pancreatoduodenectomy Unknown status NCT00809081 Phase 3
9 Gemcitabine Hydrochloride and Oxaliplatin or Observation in Treating Patients With Biliary Tract Cancer That Has Been Removed by Surgery Completed NCT01313377 Phase 3 gemcitabine hydrochloride;oxaliplatin
10 Biliary Stenting With or Without Photodynamic Therapy in Treating Patients With Locally Advanced, Recurrent, or Metastatic Cholangiocarcinoma or Other Biliary Tract Tumors That Cannot Be Removed by Surgery Completed NCT00513539 Phase 3 porfimer sodium
11 Gemcitabine With or Without Cisplatin in Treating Patients With Unresectable Locally Advanced or Metastatic Cholangiocarcinoma or Other Biliary Tract Tumors Completed NCT00262769 Phase 3 cisplatin;gemcitabine hydrochloride
12 Fluorouracil, Cisplatin, and Radiation Therapy or Gemcitabine and Oxaliplatin in Treating Patients With Nonmetastatic Biliary Tract Cancer That Cannot Be Removed By Surgery Completed NCT00304135 Phase 2, Phase 3 cisplatin;gemcitabine hydrochloride;oxaliplatin
13 Capecitabine or Observation After Surgery in Treating Patients With Biliary Tract Cancer Completed NCT00363584 Phase 3 capecitabine
14 Comprehensive Electronic Cancer Support System for the Treatment of Cancer Related Symptoms Completed NCT01640522 Phase 3
15 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
16 Ondansetron With or Without Dexamethasone to Prevent Vomiting in Patients Receiving Radiation Therapy to the Upper Abdomen Completed NCT00016380 Phase 3 dexamethasone;ondansetron
17 E-MOSAIC Electronic Tool to Monitor Symptoms Completed NCT00477919 Phase 3
18 Safety and Efficacy of Modified Folfirinox Versus Gemcis in Bile Duct Tumours Recruiting NCT02591030 Phase 2, Phase 3 GEMCIS;mFolfirinox
19 Photodynamic Therapy (PDT) for Palliation of Cholangiocarcinoma Recruiting NCT01755013 Phase 2, Phase 3
20 Early Palliative Care in Patients With Metastatic Upper Gastrointestinal Cancers Treated With First-line Chemotherapy Recruiting NCT02853474 Phase 3
21 Early Palliative Care With Standard Care or Standard Care Alone in Improving Quality of Life of Patients With Incurable Lung or Non-colorectal Gastrointestinal Cancer and Their Family Caregivers Active, not recruiting NCT02349412 Phase 3
22 Percutaneous Hepatic Perfusion vs. Cisplatin/Gemcitabine in Patients With Intrahepatic Cholangiocarcinoma Not yet recruiting NCT03086993 Phase 2, Phase 3 Cisplatin and Gemcitabine
23 Safety and Efficiency of Photodynamic Therapy for Blie Duct Carcinoma Suspended NCT01859169 Phase 2, Phase 3
24 Gemcitabine With or Without Capecitabine in Treating Patients With Locally Advanced, Unresectable, or Metastatic Biliary Cancer Terminated NCT00658593 Phase 3 capecitabine;gemcitabine hydrochloride
25 Efficacy and Safety Study of PDT Using Photofrin in Unresectable Advanced Perihilar Cholangiocarcinoma (OPUS) Terminated NCT02082522 Phase 3 Photodynamic therapy-Photofrin;Chemotherapy regimen
26 Escitalopram in Treating Depression in Patients With Advanced Lung or Gastrointestinal Cancer Terminated NCT00387348 Phase 3 escitalopram oxalate;Placebo
27 Stent Placement With or Without Photodynamic Therapy Using Porfimer Sodium as Palliative Treatment in Treating Patients With Stage III or Stage IV Cholangiocarcinoma That Cannot Be Removed By Surgery Withdrawn NCT00253617 Phase 3 porfimer sodium
28 Single-arm Study of Photodynamic Laser Therapy Using Foscan for Non-curatively-resectable Bile Duct Carcinoma Unknown status NCT01016002 Phase 2 Temoporfin
29 A Randomized, Open, Prospective Clinical Research of Fluorouracil Implant to Improve Surgical Gallbladder Cancer and Bile Duct Cancer Unknown status NCT01317069 Phase 2 Fluorouracil implant
30 Liposomal Doxorubicin in Treating Patients With Liver or Bile Duct Cancer Unknown status NCT00003296 Phase 2 pegylated liposomal doxorubicin hydrochloride
31 Chemotherapy in Treating Patients With Locally Advanced or Metastatic Cancer of the Pancreas or Bile Duct Unknown status NCT00010088 Phase 2 fluorouracil;gemcitabine hydrochloride;leucovorin calcium
32 Calcitriol in Advanced Intrahepatic Cholangiocarcinoma Unknown status NCT01039181 Phase 2 Calcitriol
33 HAI Via Interventionally Implanted Port Catheter Systems Unknown status NCT00356161 Phase 2
34 Combination Chemotherapy Plus Interferon Alfa Followed by Filgrastim in Treating Patients With Gastrointestinal Tract Cancer Unknown status NCT00019474 Phase 2 fluorouracil;hydroxyurea
35 Photodynamic Therapy in Treating Patients With Cancer of the Bile Duct, Gallbladder, or Pancreas Completed NCT00003923 Phase 2 porfimer sodium
36 Trastuzumab in Treating Patients With Locally Advanced or Metastatic Gallbladder Cancer or Bile Duct Cancer That Cannot Be Removed by Surgery Completed NCT00478140 Phase 2
37 Cabozantinib (XL-184) Monotherapy for Advanced Cholangiocarcinoma Completed NCT01954745 Phase 2 Cabozantinib
38 Irinotecan in Treating Patients With Advanced Gallbladder or Bile Duct Cancer Completed NCT00003276 Phase 2 irinotecan hydrochloride
39 A Trial Evaluating the Pharmacokinetics and Mode of Action of EndoTAG®-1 in Tumor Patients With Hepatic Metastases Completed NCT00542048 Phase 2 EndoTAG®-1
40 Gemcitabine and Capecitabine in Treating Patients With Advanced and/or Inoperable Cholangiocarcinoma or Carcinoma of the Gallbladder Completed NCT00084942 Phase 2 capecitabine;gemcitabine hydrochloride
41 S0202 Gemcitabine and Capecitabine for Unresectable Locally Advanced Metastatic Gallbladder Cancer or Cholangiocarcinoma Completed NCT00033540 Phase 2 capecitabine;gemcitabine hydrochloride
42 Gemcitabine Plus Pemetrexed Disodium in Treating Patients With Unresectable or Metastatic Biliary Tract or Gallbladder Cancer Completed NCT00059865 Phase 1, Phase 2 gemcitabine hydrochloride;pemetrexed disodium
43 Gemcitabine and Cisplatin Plus Sorafenib in Patients With Advanced Biliary Tract Carcinomas Naive to Systemic Therapy Completed NCT00919061 Phase 2 Gemcitabine;Cisplatin;Sorafenib
44 DX-8951f in Treating Patients With Biliary Cancer Completed NCT00005938 Phase 2 exatecan mesylate
45 Dolastatin 10 in Treating Patients With Metastatic Or Recurrent Liver, Bile Duct, or Gallbladder Cancer Completed NCT00003557 Phase 2 dolastatin 10
46 Combination Chemotherapy in Treating Patients With Unresectable or Metastatic Biliary Tract or Gallbladder Cancer Completed NCT00009893 Phase 2 fluorouracil;gemcitabine hydrochloride;leucovorin calcium
47 Selumetinib in Treating Patients With Biliary Cancer That Cannot Be Removed By Surgery Completed NCT00553332 Phase 2 selumetinib
48 Efficacy of Imatinib and 5-FU/Leucovorin in Patients With Advanced Carcinoma of the Gallbladder and Bile Duct Completed NCT01153750 Phase 2 Glivec
49 Gemcitabine, Oxaliplatin in Combination With Bevacizumab in Biliary Tract and Gallbladder Cancer Completed NCT00361231 Phase 2 Bevacizumab;Gemcitabine;Oxaliplatin
50 Adjuvant Palliative Capecitabine and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Biliary Tract Cancer Completed NCT00073905 Phase 2 capecitabine plus gemcitabine

Search NIH Clinical Center for Bile Duct Carcinoma

Cochrane evidence based reviews: bile duct neoplasms

Genetic Tests for Bile Duct Carcinoma

Anatomical Context for Bile Duct Carcinoma

MalaCards organs/tissues related to Bile Duct Carcinoma:

38
Liver, Testes, Lung, Skin, Pancreas, Small Intestine, Nk Cells

Publications for Bile Duct Carcinoma

Articles related to Bile Duct Carcinoma:

(show top 50) (show all 306)
# Title Authors Year
1
Impact of the histological phenotype of extrahepatic bile duct carcinoma. ( 29387397 )
2018
2
A long-term recurrence-free survival of a patient with the mixed adeno-neuroendocrine bile duct carcinoma: A case report and review of the literature. ( 28806619 )
2017
3
Reduced EBP50 expression levels are correlated with unfavorable clinicopathological features of extrahepatic bile duct carcinoma and promote the proliferation and migration of QBC939 cells. ( 28454463 )
2017
4
Mesothelin-targeting chimeric antigen receptor-modified T cells by piggyBac transposon system suppress the growth of bile duct carcinoma. ( 28381173 )
2017
5
Survival outcome and prognostic factors after pancreatoduodenectomy for distal bile duct carcinoma: a retrospective multicenter study. ( 28612115 )
2017
6
Intrapancreatic distal common bile duct carcinoma: Analysis, staging considerations, and comparison with pancreatic ductal and ampullary adenocarcinomas. ( 27469329 )
2016
7
Intra-pancreatic Distal Bile Duct Carcinoma is Morphologically, Genetically, and Clinically Distinct from Pancreatic Ductal Adenocarcinoma. ( 26956004 )
2016
8
Bile duct carcinoma recurrence in the papillary region in a long-term survivor of hilar cholangiocarcinoma: a case report. ( 27784337 )
2016
9
EGFR, COX2, p-AKT expression and PIK3CA mutation in distal extrahepatic bile duct carcinoma. ( 27020207 )
2016
10
Bile duct carcinoma associated with congenital biliary dilatation in a 16-year-old female: a case report and literature review. ( 26943681 )
2016
11
Expression and Significance of COX-2 and Ki-67 in Hepatolithiasis with Bile Duct Carcinoma. ( 26423666 )
2015
12
Bilateral ovarian metastasis from distal common bile duct carcinoma developing after choledochal cyst excision. ( 26155281 )
2015
13
Abnormal increased re-released Hb from RBCs of an intrahepatic bile duct carcinoma patient was detected by electrophoresis release test. ( 26405982 )
2015
14
Polypoid extrahepatic bile duct carcinoma morphologically indistinguishable from benign giant cell tumor. ( 26256450 )
2015
15
A case of metastatic renal cell carcinoma and bile duct carcinoma treated with a combination of sunitinib and gemcitabine. ( 26001650 )
2015
16
A case of occupational bile duct carcinoma following exposure to a chlorinated organic solvent in the printing industry that was recognized as a work-related accident. ( 25482911 )
2014
17
How to access photodynamic therapy for bile duct carcinoma. ( 25332999 )
2014
18
When hepatic-side ductal margin is positive in N+ cases, additional resection of the bile duct is not necessary to render the negative hepatic-side ductal margin during surgery for extrahepatic distal bile duct carcinoma. ( 24657986 )
2014
19
A novel technique for endoscopic transpapillary "mapping biopsy specimens" of superficial intraductal spread of bile duct carcinoma (with videos). ( 24674353 )
2014
20
Diagnostic and prognostic value of immunohistochemical expression of S100P and IMP3 in transpapillary biliary forceps biopsy samples of extrahepatic bile duct carcinoma. ( 23269460 )
2013
21
Pancreaticobiliary maljunction is associated with common bile duct carcinoma: a meta-analysis. ( 24489507 )
2013
22
Chemoradiation and brachytherapy in extrahepatic bile duct carcinoma. ( 24289902 )
2013
23
Characterization of two novel cell lines with distinct heterogeneity derived from a single human bile duct carcinoma. ( 23382894 )
2013
24
Descriptive epidemiology of bile duct carcinoma in Osaka. ( 24014885 )
2013
25
Bile duct carcinoma involving the common channel associated with pancreaticobiliary maljunction shows an extension pattern similar to ductal carcinoma of the pancreas. ( 23957917 )
2013
26
Differential expression of basement membrane type IV collagen I+2 and I+6 chains as a prognostic factor in patients with extrahepatic bile duct carcinoma. ( 22927259 )
2013
27
Synergic effect of photodynamic therapy using talaporfin sodium with conventional anticancer chemotherapy for the treatment of bile duct carcinoma. ( 22835954 )
2013
28
Extended right hepatectomy for hilar bile duct carcinoma using the modified liver hanging maneuver. ( 22683977 )
2012
29
Photodynamic therapy using talaporfin sodium (LaserphyrinAr) for bile duct carcinoma: a preliminary clinical trial. ( 23155262 )
2012
30
Bile aspiration cytology in diagnosis of bile duct carcinoma: factors associated with positive yields. ( 21785970 )
2012
31
Adenocarcinoma with pyloric gland phenotype of the extrahepatic bile ducts: a previously unrecognized and distinctive morphologic variant of extrahepatic bile duct carcinoma. ( 22795356 )
2012
32
Duct of Luschka diagnosed by sonography in a patient with bile duct carcinoma and intrahepatic bile duct dilatation. ( 23055263 )
2012
33
Aggressive hilar inflammatory myofibroblastic tumor with hilar bile duct carcinoma in situ. ( 22319741 )
2011
34
Post-cholecystectomy amputation neuroma mimicking common bile duct carcinoma. ( 21861328 )
2011
35
Down-regulation of c-Myc expression inhibits the invasion of bile duct carcinoma cells. ( 21557726 )
2011
36
Advantages of laserphyrin compared with photofrin in photodynamic therapy for bile duct carcinoma. ( 21360081 )
2011
37
Extensively spreading intraepithelial bile duct carcinoma causing multiple bile duct strictures: report of three cases. ( 21969205 )
2011
38
Endoscopic diagnosis of extrahepatic bile duct carcinoma: Advances and current limitations. ( 21611097 )
2011
39
Pancreatoduodenectomy for local intrapancreatic recurrence after bile duct resection of mid bile duct carcinoma. ( 21410028 )
2010
40
Expression of the extracellular matrix protein periostin in liver tumours and bile duct carcinomas. ( 20459570 )
2010
41
Efficacy and safety of capecitabine in combination with docetaxel and mitomycin C in patients with pre-treated pancreatic, gallbladder, and bile duct carcinoma. ( 20224968 )
2010
42
Decreased expression of focal adhesion kinase is associated with a poor prognosis in extrahepatic bile duct carcinoma. ( 20185162 )
2010
43
The ratio between metastatic and examined lymph nodes is an independent prognostic factor for patients with resectable middle and distal bile duct carcinoma. ( 19596119 )
2010
44
Impact of residual in situ carcinoma on postoperative survival in 125 patients with extrahepatic bile duct carcinoma. ( 19521656 )
2010
45
Antiproliferation and apoptosis induced by tamoxifen in human bile duct carcinoma QBC939 cells via upregulated p53 expression. ( 19460356 )
2009
46
Depth of tumor invasion better predicts prognosis than the current American Joint Committee on Cancer T classification for distal bile duct carcinoma. ( 19628081 )
2009
47
Main bile duct carcinoma management. Our experience on 38 cases. ( 19681291 )
2009
48
Choleretic effect of inchinkoto, a herbal medicine, on livers of patients with biliary obstruction due to bile duct carcinoma. ( 19054142 )
2009
49
67-kDa laminin receptor in human bile duct carcinoma. ( 19182490 )
2009
50
A novel approach for treatment of unresectable extrahepatic bile duct carcinoma: design of radioactive stents and an experimental trial in healthy pigs. ( 19231492 )
2009

Variations for Bile Duct Carcinoma

Cosmic variations for Bile Duct Carcinoma:

9 (show top 50) (show all 694)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM4172016 TSC1 biliary tract,bile duct,carcinoma,adenocarcinoma c.737+1G>A p.? 16
2 COSM308173 TRIM28 biliary tract,bile duct,carcinoma,adenocarcinoma c.1475G>T p.R492L 16
3 COSM10656 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.742C>T p.R248W 16
4 COSM44329 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.470T>A p.V157D 16
5 COSM10777 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.715A>G p.N239D 16
6 COSM45050 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.871A>G p.K291E 16
7 COSM43687 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.641A>G p.H214R 16
8 COSM10704 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.844C>T p.R282W 16
9 COSM10663 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.916C>T p.R306* 16
10 COSM10660 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.818G>A p.R273H 16
11 COSM10654 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.637C>T p.R213* 16
12 COSM44326 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.706T>C p.Y236H 16
13 COSM45393 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.793C>A p.L265M 16
14 COSM44114 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.826G>A p.A276T 16
15 COSM10725 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.701A>G p.Y234C 16
16 COSM43842 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.770T>C p.L257P 16
17 COSM44823 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.981T>G p.Y327* 16
18 COSM10731 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.707A>G p.Y236C 16
19 COSM43778 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.713G>T p.C238F 16
20 COSM44426 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.568C>G p.P190A 16
21 COSM44785 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.702C>G p.Y234* 16
22 COSM11582 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.395A>G p.K132R 16
23 COSM43751 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.673-1G>A p.? 16
24 COSM44523 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.863A>G p.N288S 16
25 COSM10727 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.438G>A p.W146* 16
26 COSM44786 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.694A>C p.I232L 16
27 COSM43596 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.841G>A p.D281N 16
28 COSM10690 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.473G>A p.R158H 16
29 COSM44262 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.808T>C p.F270L 16
30 COSM11078 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.1027G>T p.E343* 16
31 COSM11356 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.726C>G p.C242W 16
32 COSM10883 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.731G>A p.G244D 16
33 COSM10672 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.577C>T p.H193Y 16
34 COSM11355 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.737T>C p.M246T 16
35 COSM44226 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.380C>T p.S127F 16
36 COSM10893 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.824G>A p.C275Y 16
37 COSM45025 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.488A>C p.Y163S 16
38 COSM44623 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.487T>A p.Y163N 16
39 COSM44271 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.688A>C p.T230P 16
40 COSM44463 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.848G>T p.R283L 16
41 COSM10742 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.578A>G p.H193R 16
42 COSM43909 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.817C>A p.R273S 16
43 COSM3728361 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.782+2T>G p.? 16
44 COSM10687 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.527G>A p.C176Y 16
45 COSM308164 SYNJ2 biliary tract,bile duct,carcinoma,adenocarcinoma c.811C>A p.L271M 16
46 COSM308304 SMAD4 biliary tract,bile duct,carcinoma,adenocarcinoma c.1659A>G p.*553W 16
47 COSM84440 SMAD4 biliary tract,bile duct,carcinoma,adenocarcinoma c.346C>T p.Q116* 16
48 COSM14169 SMAD4 biliary tract,bile duct,carcinoma,adenocarcinoma c.988G>A p.E330K 16
49 COSM308305 SMAD4 biliary tract,bile duct,carcinoma,adenocarcinoma c.404G>A p.R135Q 16
50 COSM308146 SEMA5A biliary tract,bile duct,carcinoma,adenocarcinoma c.2170C>A p.H724N 16

Expression for Bile Duct Carcinoma

Search GEO for disease gene expression data for Bile Duct Carcinoma.

Pathways for Bile Duct Carcinoma

Pathways related to Bile Duct Carcinoma according to GeneCards Suite gene sharing:

(show all 36)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.32 CCND1 FASLG MUC1 MYC NCAM1 PTGS2
2
Show member pathways
12.67 CCND1 CDH1 CDX2 MUC2 MYC TP53
3
Show member pathways
12.66 CDH1 FASLG MAPK8 PTGS2 TP53
4 12.63 CCND1 CDH1 FASLG MAPK8 MYC PTGS2
5 12.46 CDH1 KRT19 KRT20 KRT7 MUC1
6
Show member pathways
12.43 CCND1 FASLG MAPK8 MYC PTGS2 TP53
7
Show member pathways
12.39 CDH1 MAPK8 MUC1 MYC TP53
8 12.37 CCND1 MAPK8 MYC TP53
9
Show member pathways
12.34 CCND1 FASLG MYC TP53
10 12.31 CCND1 CDH1 MYC TP53
11 12.24 CCND1 FASLG MYC TP53
12
Show member pathways
12.2 CCND1 FASLG MAPK8 TP53
13 12.13 CCND1 CDH1 MAPK8 MYC PTGS2 TP53
14 12.09 CCND1 CDH1 MYC TP53
15
Show member pathways
12.08 CCND1 MAPK8 MYC TP53
16 12.02 CCND1 CDH1 MYC PTGS2 TP53
17 11.99 CDX2 KRT19 MYC NCAM1
18 11.98 CCND1 MAPK8 MYC TP53
19 11.92 CCND1 MYC PTGS2 TP53
20 11.78 CCND1 MYC TP53
21 11.75 CCND1 MYC PTGS2 TP53
22 11.73 CCND1 CDH1 MYC
23 11.72 CCND1 MYC PTGS2
24 11.68 ABCC2 FASLG TP53
25 11.62 CCND1 CDH1 MYC TP53
26 11.61 CCND1 FASLG MAPK8 MYC TP53
27 11.52 CCND1 MAPK8 MYC
28 11.49 CCND1 MYC TP53
29 11.49 CCND1 FASLG MUC1 MYC PTGS2 TP53
30 11.41 CCND1 MYC TP53
31 11.4 FASLG MAPK8 TP53
32 11.33 CCND1 FASLG MAPK8 TP53
33 11.27 KRT19 PTGS2 TP53
34 11.05 ABCC2 ABCC3 MAPK8
35 10.81 CCND1 FASLG MAPK8 MYC PTGS2 TP53
36 10.64 ABCC2 ABCC3

GO Terms for Bile Duct Carcinoma

Cellular components related to Bile Duct Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 intermediate filament GO:0005882 8.92 KRT19 KRT20 KRT7 KRT9

Biological processes related to Bile Duct Carcinoma according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 viral process GO:0016032 9.91 KRT19 KRT7 NCAM1 RPSA TP53
2 keratinization GO:0031424 9.78 KRT19 KRT20 KRT7 KRT9
3 response to estrogen GO:0043627 9.67 ABCC2 CCND1 KRT19
4 O-glycan processing GO:0016266 9.63 MUC1 MUC2 MUC4
5 ATP hydrolysis coupled anion transmembrane transport GO:0099133 9.56 ABCC2 ABCC3
6 ovulation GO:0030728 9.55 MYC PTGS2
7 maintenance of gastrointestinal epithelium GO:0030277 9.54 MUC2 MUC4
8 cellular response to UV GO:0034644 9.54 MYC PTGS2 TP53
9 mitotic G1 DNA damage checkpoint GO:0031571 9.52 CCND1 TP53
10 cellular chloride ion homeostasis GO:0030644 9.43 ABCC2 FASLG
11 positive regulation of cell cycle GO:0045787 9.43 CCND1 MYC TP53
12 re-entry into mitotic cell cycle GO:0000320 9.4 CCND1 MYC
13 response to organonitrogen compound GO:0010243 9.33 CCND1 PTGS2 TP53
14 canalicular bile acid transport GO:0015722 9.32 ABCC2 ABCC3
15 cornification GO:0070268 9.26 KRT19 KRT20 KRT7 KRT9
16 response to drug GO:0042493 9.1 ABCC2 CCND1 CDH1 MYC PTGS2 TP53

Molecular functions related to Bile Duct Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 ATPase-coupled anion transmembrane transporter activity GO:0043225 8.62 ABCC2 ABCC3

Sources for Bile Duct Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....